News
-
-
PRESS RELEASE
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
NanoViricides, Inc. highlights the strong effectiveness of its broad-spectrum antiviral drug NV-387 against various viruses. Expected to drive significant valuation and market share, leading to rapid regulatory approvals and early revenues -
-
PRESS RELEASE
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies -
-
PRESS RELEASE
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc. comments on WHO's extension of the MPox Public Health Emergency of International Concern and highlights the development of NV-387, a potential broad-spectrum antiviral for MPOX treatment -
-
PRESS RELEASE
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc. announces design completion of adaptive clinical trial protocol for MPox Virus treatment. Trial to evaluate dosing regimen, safety, and effectiveness in 80 patients -
-
PRESS RELEASE
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox
